What changed recently

Newly published and updated guidelines across every system, newest first. Each entry links to the official source.

All systems Cardiovascular Respiratory Gastrointestinal & Hepatology Renal & Genitourinary Endocrine & Metabolic Reproductive & Women's Health Hematology & Oncology Musculoskeletal & Rheumatology Dermatology Neurology & Special Senses Psychiatry & Behavioral Immunology & Allergy Infectious Disease Emergency & Critical Care Pediatrics Preventive Medicine & Primary Care Dental & Oral Health

5 older updates are outside this window. Show all time

Immunology & AllergyUS2026-04-012015 → 2025 practice parameter
Primary immunodeficiency
The 2025 parameter abandons the previous edition's structure of working through individual genetic entities and instead organises recommendations into a diagnosis part and a management part. Diagnosis now covers newborn screening for severe combined immunodeficiency, genetic testing and comorbidity surveillance, while management addresses immunoglobulin replacement, antibiotic prophylaxis, haematopoietic stem cell transplantation, precision medicine and quality-of-life assessment.
source ↗curation confidence 90%
Immunology & AllergyEU2025-12-012016 revision → ARIA-EAACI 2024-2025 revision, Part I
Allergic rhinitis
This ARIA revision rebuilds the intranasal treatment recommendations around eleven prioritised questions using the GRADE evidence-to-decision framework, drawing on mHealth and pharmacovigilance data and an expert cost survey alongside systematic reviews. It now suggests a fixed combination of intranasal antihistamine plus intranasal corticosteroid ahead of either agent alone, and intranasal corticosteroid ahead of intranasal antihistamine when a single agent is used.
source ↗curation confidence 80%
Immunology & AllergyEU2024-10-302014 → 2025
Food allergy
This revision of the 2014 EAACI food allergy management guideline (which also absorbs the 2018 food immunotherapy guideline) shifts the emphasis from avoidance and watchful waiting to active management, recommending oral, sublingual and epicutaneous immunotherapy for peanut allergy plus oral immunotherapy for egg and milk, and incorporating omalizumab following its US approval for IgE-mediated food allergy from age one. It adds a conditional recommendation for psychological support in patients with significant anxiety and a strong recommendation to keep eating tolerated foods to protect nutrition.
source ↗